

a series of fact sheets written
by experts in the field of liver
disease

HCV Treatment:

Reporting Drug Side Effects

Alan Franciscus, Editor-in-Chief

PRIOR TO THE RELEASE OF A NEW MEDICATION, clinical studies are conducted that ‘test’ a drug for safety, effectiveness and other important issues before marketing approval. Safety is given the highest priority when testing a new drug.

Nevertheless, sometimes drugs slip through the cracks, and the results can be life-threatening. The problem is that most clinical trials study the ‘easiest’ populations so that the results are more favorable to the pharmaceutical company. Also, even though there are between 1,000-3,000 people being treated, no complete picture develops until the drug is released to the general public (with that condition).

In the FDA Drug Safety Newsletter, an overview of the FDA approved drug atomoxetine (brand name Strattera) was discussed. Atomoxetine was approved on November 26, 2002 as the first non-stimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) in children (ages 6 and above) and adults. In the period between 2002 to 2007 about 3.3 million people received a prescription of atomoxetine (about 64% were children 17 years or younger). Liver injury was only found after the drug was approved. In 2004,

after 2 published reports, the FDA added a bolded warning about severe liver injury associated with the drug. Six additional reports of serious liver injury since 2004 were reported to the FDA, which prompted a revised product label that included stronger language in 2007.

The FDA also advised healthcare professionals and patients to be aware and report any further cases to the FDA’s MedWatch. Between January 2005 and March 19, 2008 there have been six more events reported to the Adverse Events Reporting System (AERS). Based on these reports the FDA is continuing to monitor the adverse events.

Again all of these events were AFTER the drug was FDA approved. This is important information to know and as providers and patients we must report any adverse events directly to the FDA. This will be even more important when the newer HCV drugs are approved and marketed so that any severe or potentially life-threatening conditions can be avoided.

Reporting Adverse Events

Report serious adverse events to FDA’s MedWatch reporting system:

- by completing an online form at www.fda.gov/medwatch/report.htm,
- by faxing (1-800-FDA-0178),
- by mail using the pre-paid postage address form provided online (5600 Fishers Lane, Rockville, MD 20852-9787),
- by telephone (1-800-FDA-1088).

Source:

FDA Drug Safety Newsletter www.fda.gov/cder/dsn/default.htm, Volume 2/number 1/2009

See also: “What the Heck is Hepatotoxicity?” by Lucinda K. Porter, *HCV Advocate*, June 2009.

To recap the clinical trial process:

- Pre-clinical trials are conducted basically in a test tube.
- Phase 1 trials are small studies (~20-80 people) that evaluate the safety, determine a safe dose and identify side effects. Phase 1 studies involve both healthy people (without the condition or disease) and patients with the condition for which the drug is intended.
- Phase II studies are larger studies (~100-300 patients) that continue to evaluate the safety and effectiveness of the drug in patients with the targeted condition. If you look at HCV drugs in development you will find that the vast majority of drugs that reach phase II studies are cancelled due to lack of effectiveness or safety concerns. Since more patients are using the experimental drug it will give a better picture of the safety and effectiveness.
- Phase III studies are large studies (~1,000-3,000 patients) that continue to evaluate safety and effectiveness and also compare the new drug to the standard of care. If a drug is found to be as effective as the current standard of care and if there are no extreme safety issues, the pharmaceutical company will apply to the FDA for marketing approval. Phase III studies have a much larger patient population and, as a result, will give a much better picture of the safety and effectiveness of the study drug.
- Phase IV or post-marketing studies are conducted to find out about treating sub-populations with the same condition that may not have been included in the original studies or for the treatment of a different condition.

Be Sure to Check Out the Other Factsheets in This Series

HCV Treatment

- Adherence to HCV Therapy
- Hepatitis E (HEV)
- Interferon and Ribavirin
- Patient Assistance Programs
- Pegasys plus Copegus FDA Package Insert
- PegIntron plus Rebetol FDA Package Insert
- Predictors of HCV Treatment Response
- Pregnancy Categories
- Ribasphere (ribavirin) FDA Package Insert
- Treatment Response Terms
- Types of Interferon & How They Work

For more information about hepatitis C, hepatitis B and HCV coinfections, please visit www.hcvadvocate.org.

• hcsPFACTsheet •

A publication of the Hepatitis C Support Project

Executive Director

Editor-in-Chief, HCSP Publications
Alan Franciscus

Design

Paula Fener

Production

C.D. Mazoff, PhD

Contact information:

Hepatitis C Support Project
PO Box 427037
San Francisco, CA 94142-7037

alanfranciscus@hcvadvocate.org

The information in this fact sheet is designed to help you understand and manage HCV and is not intended as medical advice. All persons with HCV should consult a medical practitioner for diagnosis and treatment of HCV.

This information is provided by the Hepatitis C Support Project • a nonprofit organization for HCV education, support and advocacy • © 2009 Hepatitis C Support Project • Reprint permission is granted and encouraged with credit to the Hepatitis C Support Project.



HCV ADVOCATE
www.hcvadvocate.org